All Outputs (2)

FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes (2022)
Journal Article
Samms, R. J., Cheng, C. C., Fourcaudot, M., Heikkinen, S., Khattab, A., Adams, J., …Norton, L. (2022). FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes. AJP - Endocrinology and Metabolism, 323(2), E123-E132. https://doi.org/10.1152/ajpendo.00050.2022

Fibroblast growth factor 21 (FGF21) is increased acutely by carbohydrate ingestion and is elevated in patients with type 2 diabetes (T2D). However, the physiological significance of increased FGF21 in humans remains largely unknown. We examined wheth... Read More about FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.

Acute effects of prior dietary fat ingestion on postprandial metabolic responses to protein and carbohydrate co-ingestion in overweight and obese men: A randomised crossover trial (2022)
Journal Article
Wilhelmsen, A., Davies, A., Mallinson, J., Pabla, P., Jones, R., Palmer, E. A., …Tsintzas, K. (2022). Acute effects of prior dietary fat ingestion on postprandial metabolic responses to protein and carbohydrate co-ingestion in overweight and obese men: A randomised crossover trial. Clinical Nutrition, 41(8), 1623-1635. https://doi.org/10.1016/j.clnu.2022.06.022

Background: Obesity and insulin resistance are associated with an impaired sensitivity to anabolic stimuli such as dietary protein (anabolic resistance). Omega-3 polyunsaturated fatty acids (n-3 PUFA) may be protective against the deleterious effects... Read More about Acute effects of prior dietary fat ingestion on postprandial metabolic responses to protein and carbohydrate co-ingestion in overweight and obese men: A randomised crossover trial.